ArticleCase reports in women's health2026
Complete hydatidiform mole with coexisting fetus: A case report.
Article in Case reports in women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Complete hydatidiform mole in one twin after embryo transfer: a case report and literature review.Frontiers in medicine · 2026Article
- Living Newborn Back-To-Back With a Complete Hydatidiform Mole: A Rare Twin Pregnancy Outcome.Case reports in obstetrics and gynecology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Complete hydatidiform mole with coexisting fetus (CHMCF) is an exceptionally rare and clinically challenging obstetric condition. Its diagnosis and management require a high index of suspicion and a multidisciplinary approach. This report presents the case of a woman in her 30s who presented for a routine prenatal examination at 15 weeks of gestation. Ultrasonography revealed a placenta with a mixed echogenicity area exhibiting a characteristic honeycomb-like appearance, alongside a coexisting viable fetus with normal biometry. Serum β-human chorionic gonadotropin (β-hCG) was markedly elevated at 259,762 mIU/mL. Through serial monitoring and multidisciplinary consultation, a diagnosis of CHMCF was suspected and later confirmed by postnatal genetic analysis. The pregnancy was complicated by persistent vaginal bleeding at 21 weeks, leading to termination following a comprehensive risk-benefit assessment. This case underscores the diagnostic challenges, the critical role of cytogenetic analysis, the importance of patient counseling regarding the significantly elevated risks of obstetric complications and gestational trophoblastic neoplasia (GTN), and the necessity for meticulous post-evacuation surveillance. This report aims to enhance clinical awareness and outline a structured management protocol for this rare entity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.